Aeon closes seed extension, acquires Germany's leading consumer blood diagnostics platform

Zurich based Aeon, the preventive healthcare company pioneering AI-powered whole-body health check-ups, today announces the close of its seed extension and the acquisition of the core assets of Aware Health, Germany's leading consumer blood diagnostics platform. Aeon is now the first European platform to offer a continuous, longitudinal health picture, combining whole-body imaging with recurring blood diagnostics in a single product, with AI turning that data into personalised risk prediction.

This seed extension brings Aeon's total seed funding to over USD 14 million. The extension was co-led by Araya Ventures with participation from existing investors Concentric, GoHub Ventures, Kadmos Capital, Calm/Storm Ventures, N&V Capital, and Bigwave Capital, and funds the integration of Aware Health's technology and team alongside Aeon's accelerated European roadmap.

From Detection to Prediction

Whole-body MRI is powerful but episodic. Blood testing is recurring. By combining both, Aeon creates something that has not previously existed in Europe: a continuous, longitudinal health record per customer, updated quarter after quarter. This is exactly the data foundation AI needs. While single measurements show a snapshot, longitudinal multimodal data lets Aeon's AI models detect trends, flag deviations early, and predict individual health risks before they become disease. Today, more than 90 percent of Aeon check-ups already surface findings customers can act on, with a significant finding rate of 15.4 percent.

"We are redefining preventive care by shifting it from reaction to action," said Tim Seithe, Founder and CEO of Aeon. "Imaging tells you where you are. Blood diagnostics tell you where you are heading. AI is what connects the two into prediction. The acquisition of Aware Health accelerates that vision by two years, and this round gives us everything we need to execute."

"Aeon is building something genuinely new in European healthcare," said Rupa Popat, Founder and Managing Partner at Araya Ventures. "The combination of imaging, recurring blood diagnostics, and AI creates a longitudinal health picture that no other platform in Europe offers. We are proud to back Tim and the team at this moment."

Doubling Down on AI

Alongside the acquisition, Aeon has significantly strengthened its AI team. Pablo Tano joins as AI Lead. Tano has published in Nature on reinforcement learning in the brain, co-authored research with leading figures in the field including Peter Dayan and Alexandre Pouget, and was part of the winning team of Meta's global MyoChallenge, an international AI competition. At Aeon, he leads the development of the platform's intelligence layer: AI models that read across imaging, blood biomarkers, and genetic data to deliver personalised risk prediction and individually tailored health interventions for every customer.

The Aware Health Acquisition

Aware Health built one of Germany’s leading consumer blood diagnostics platforms, combining a fully regulated diagnostics stack with live laboratory integrations and a network of more than 45 blood-draw locations. The platform offered 100+ biomarkers across a wide range of preventive health test panels and served close to 10,000 active customers.

Aeon acquired the full technology platform, key contracts and equipment, the customer relationships, and the core team. The Berlin team continues under the Aeon brand without interruption. For Aeon's AI roadmap, the acquisition adds a critical asset: a longitudinal biomarker dataset built from recurring testing, the raw material for training predictive health models.

“What I am most proud of is what our team built at Aware: a trusted consumer health brand and a platform that made advanced diagnostics accessible and easy to understand.”” said Ferdinand Schmidt-Thomé, co-founder of Aware Health. “The acquisition gives what we built the opportunity to continue growing as part of a broader preventive-health offering. The combination with whole-body imaging and Aeon's AI genuinely changes what preventive health looks like in Europe."

Customer data will only be transferred with each customer’s explicit individual consent and in accordance with GDPR.

Scaling Germany

Aeon has been live in Germany since early 2026, and Germany is already its fastest-growing market. The acquisition adds what would have taken years to build: a regulated diagnostics stack, live laboratory integration, a nationwide draw-location network, and an established base of loyal customers in Europe's largest healthcare economy. Combined with the seed extension, Aeon enters this next phase funded, integrated, and positioned to consolidate the preventive health category across Europe.